RIGEL PHARMACEUTICALS INC
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Accelerated filer
State of Incorporation
DE
Business Address
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA, 94080
Mailing Address
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA, 94080
Phone
650-624-1100
Fiscal Year End
1231
EIN
943248524
Financial Overview
FY2025
$367.02M
Net Income
$56.75M
Cash & Equivalents
$20.40
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | March 27, 2026 | View on SEC |
| 8-K Current report of material events | March 3, 2026 | View on SEC |
| 10-K Annual financial report | March 3, 2026 | View on SEC |
| 4 Insider stock transaction report | February 24, 2026 | View on SEC |
| 4 Insider stock transaction report | February 19, 2026 | View on SEC |
| 4 Insider stock transaction report | February 19, 2026 | View on SEC |
| 4 Insider stock transaction report | February 19, 2026 | View on SEC |
| 4 Insider stock transaction report | February 19, 2026 | View on SEC |
| 4 Insider stock transaction report | February 19, 2026 | View on SEC |
| 4 Insider stock transaction report | February 12, 2026 | View on SEC |
Annual Reports
10-K
March 3, 2026
- Strategic acquisition of Gavreto significantly expands Rigel's oncology portfolio and leverages existing commercial infrastructure.
- Fostamatinib (TAVALISSE/TAVLESSE) continued strong product sales growth, demonstrating sustained market acceptance and boosting overall revenue.
Insider Trading
SELL
1 insiders
1 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.